Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 14/20 | 0.55 |
| ▸ | KCNA5 | P22460 | 3/20 | 0.49 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 11/20 | 0.46 |
| ▸ | PLD1 | Q13393 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.44 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.44 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.44 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.44 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1514881 | 1.00 | SLC6A4 (0.55) | SLC6A4KCNA5KCNE1SLC6A2PLD1 | |
| Hydrochloric Acid SCHEMBL5453223 | 0.84 | SLC6A4 (0.48) | SLC6A4SLC6A2CYP3A4CYP2D6KCNH2 | |
| SCHEMBL12806765 | 0.84 | SLC6A4 (0.53) | SLC6A4KCNA5KCNE1SLC6A2PLD1 | |
| SCHEMBL9963444 | 0.83 | KCNA5 (0.50) | SLC6A4KCNA5KCNE1CYP2D6KCNH2 | |
| SCHEMBL1991270 | 0.82 | POLB (0.51) | KCNA5KCNE1KCNH2ALDH1A1 | |
| SCHEMBL12806779 | 0.80 | SLC6A4 (0.50) | SLC6A4KCNA5KCNE1SLC6A2PLD1 | |
| SCHEMBL2673019 | 0.80 | KCNA5 (0.49) | SLC6A4KCNA5KCNE1PLD1CYP3A4 | |
| SCHEMBL9933454 | 0.80 | KCNA5 (0.49) | SLC6A4KCNA5KCNE1PLD1CYP3A4 | |
| SCHEMBL9933193 | 0.80 | KCNA5 (0.49) | SLC6A4KCNA5KCNE1PLD1CYP3A4 | |
| SCHEMBL12806743 | 0.79 | SLC6A4 (0.49) | SLC6A4KCNA5KCNE1SLC6A2PLD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2470021-B1 | NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME (US) | 2014-10-22 | — | — | EP | disclosed |
| US-8354403-B2 | Pyrrolidine derived beta 3 adrenergic receptor agonists | MERCK SHARP & DOHME CORP. (US) | 2013-01-15 | — | — | US | disclosed |
| US-8354403-B2 | Pyrrolidine derived beta 3 adrenergic receptor agonists | MERCK SHARP & DOHME CORP. (US) | 2013-01-15 | — | — | US | disclosed |
| US-8354403-B2 | Pyrrolidine derived beta 3 adrenergic receptor agonists | MERCK SHARP & DOHME CORP. (US) | 2013-01-15 | — | — | US | disclosed |
| US-20120157432-A1 | NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME, CORP. (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120157432-A1 | NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME, CORP. (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120157432-A1 | NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME, CORP. (US) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157432-A1 | NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS | ADRB3, ADRB1, ADRB2 | SLC6A4 1928/4885KCNA5 865/4885KCNE1 1207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.